<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FB769164-598E-48A7-94A0-AF09C6A77E95"><gtr:id>FB769164-598E-48A7-94A0-AF09C6A77E95</gtr:id><gtr:name>National Institute for Nuclear Physics</gtr:name><gtr:address><gtr:line1>via S.Sofia 62,</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C33876E8-7958-41F0-87A6-095798CF94F9"><gtr:id>C33876E8-7958-41F0-87A6-095798CF94F9</gtr:id><gtr:name>Academy of Sciences of the Czech Republic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3879A64-1F19-4F1B-9F13-2148EFBEC73D"><gtr:id>F3879A64-1F19-4F1B-9F13-2148EFBEC73D</gtr:id><gtr:name>Massachusetts General Hospital</gtr:name><gtr:address><gtr:line1>Massachusetts General Hospital</gtr:line1><gtr:line2>55 Fruit STreet</gtr:line2><gtr:postCode>MA 02114</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0663CDBB-EFF4-4415-82CE-FFA297418472"><gtr:id>0663CDBB-EFF4-4415-82CE-FFA297418472</gtr:id><gtr:name>Prague Protontherapy Centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Medicine Dentistry and Biomedical Sci</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FB769164-598E-48A7-94A0-AF09C6A77E95"><gtr:id>FB769164-598E-48A7-94A0-AF09C6A77E95</gtr:id><gtr:name>National Institute for Nuclear Physics</gtr:name><gtr:address><gtr:line1>via S.Sofia 62,</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C33876E8-7958-41F0-87A6-095798CF94F9"><gtr:id>C33876E8-7958-41F0-87A6-095798CF94F9</gtr:id><gtr:name>Academy of Sciences of the Czech Republic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3879A64-1F19-4F1B-9F13-2148EFBEC73D"><gtr:id>F3879A64-1F19-4F1B-9F13-2148EFBEC73D</gtr:id><gtr:name>Massachusetts General Hospital</gtr:name><gtr:address><gtr:line1>Massachusetts General Hospital</gtr:line1><gtr:line2>55 Fruit STreet</gtr:line2><gtr:postCode>MA 02114</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0663CDBB-EFF4-4415-82CE-FFA297418472"><gtr:id>0663CDBB-EFF4-4415-82CE-FFA297418472</gtr:id><gtr:name>Prague Protontherapy Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2D281208-9DBE-4396-87B0-99B47743F485"><gtr:id>2D281208-9DBE-4396-87B0-99B47743F485</gtr:id><gtr:firstName>Fred</gtr:firstName><gtr:surname>Currell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/136654A9-BB23-46CB-B2F5-F63954A54F71"><gtr:id>136654A9-BB23-46CB-B2F5-F63954A54F71</gtr:id><gtr:firstName>Giuseppe</gtr:firstName><gtr:surname>Schettino</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90706D80-C881-41BE-A521-79C8E15783C2"><gtr:id>90706D80-C881-41BE-A521-79C8E15783C2</gtr:id><gtr:firstName>Kevin Michael</gtr:firstName><gtr:surname>Prise</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100014"><gtr:id>E9562667-B8C7-445A-AD2F-5416A8A403A1</gtr:id><gtr:title>Biological Effectiveness Of Ion Beams for Cancer Therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100014</gtr:grantReference><gtr:abstractText>Cancer radiotherapy employing charged particles (i.e. protons and carbon ions) is currently the fastest growing cancer treatment approach with over 30 centres worldwide and an extra 30 (including 3 in the UK) planned to be operational in the next 3-5 years. Compared to conventional photon based approaches, the energy deposition profiles of ion beams are such that their destructive power can be better confined to the tumour volume with minimal damage to surrounding healthy tissues. However, despite the impressive tumour control probabilities reported, there are still uncertainties on the biological effects caused by ion beams especially related to late effects in healthy tissues which prevent further optimization of cancer particle therapy. Ultimately, it is normal tissue effects, including risks of secondary cancers, which will determine the treatment outcome. The main issue is related to the change of biological effectiveness as the ions penetrate into the tissue and a higher probability of inducing late effects when compared to X-rays. Current lack of experimental data is forcing treatment plans to adopt broadly averaged parameters for estimating tumour cell killing and neglect late effects. This project aims to investigate in parallel DNA damage, acute and late cellular effect in a variety of normal and cancerous cell lines induced by therapeutically relevant ion beams across and around their trajectory. Our central hypothesis is that damage and cellular response will vary greatly along and around the ion path as a function of depth, energy deposited, cell line and ion characteristics. Data collected will help improving current knowledge of the biological effectiveness along the ion path and how it varies with physical and biological parameters. Attention will be focused on late effects and how biological depth curves for radiation risks need to be further investigated and included in existing models in order to design optimal cancer treatment strategies. Additionally, we anticipate DNA damage caused by secondary electrons and cell signalling to have non-negligible effects whose contribution to the cancer treatment plans has still to be fully investigated.</gtr:abstractText><gtr:technicalSummary>Cancer radiotherapy employing charged particles (i.e. protons and carbon ions) is currently the fastest growing cancer treatment approach with over 30 centres worldwide and an extra 30 (including 3 in the UK) planned to be operational in the next 3-5 years. Despite the impressive results so far reported, there are still uncertainties on the biological effects caused by ion beams especially related to non-lethal and late effects in healthy tissues which prevent further optimization of cancer particle therapy. The main issue is related to the change of biological effectiveness as the ions penetrate into the tissue and a higher probability of inducing late effects when compared to X-rays. Ultimately, it is normal tissue effects, including risks of secondary cancers, which will determine the treatment outcome. Current lack of experimental data is forcing treatment plans to adopt broadly averaged parameters for estimating tumour cell killing and neglect late effects. More accurate investigations are therefore essential to develop a rigorous theory of ion radiation action at cellular and molecular level to further improve tumour hadrontherapy. Experimental studies investigating the biological response of charged particles have focused mainly on the cell killing effect of tumour cells or tissues at the Bragg peak. Damage caused at the beam entrance channel, beyond the Bragg peak and indeed in the immediate proximity of the ion path is unavoidable and needs to be addressed. Our central hypothesis is that damage and cellular response will vary greatly along and around the ion path as a function of both physics and biological parameters (i.e. depth, physical dose, cell line, ion characteristics). Using a variety of approaches, the present proposal aims to investigate in parallel DNA damage, acute and sub-lethal cellular response caused by therapeutically relevant ion beams (mainly protons but also carbon ions) on a range of normal and cancerous cell lines along the ion path and in its proximity. Data collected will help evaluating more accurate RBE values to be included in new and existing models to design optimal cancer treatment strategies. Determination of biological Bragg curves for radiation risks including late effects will provide critical information for the development and improvement of biological models aimed to improve the therapeutic use of ion beams. Additionally, we anticipate DNA damage caused by secondary electrons and cell signalling between exposed and un-exposed samples to play a non-negligible role whose contribution to cancer treatment plans has still to be fully investigated.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>496334</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with the Clatterbridge Oncology Centre Proton Therapy Facility</gtr:description><gtr:id>0A4951ED-F0C2-4AB2-9F33-D36A96519112</gtr:id><gtr:impact>Draft manuscript in preparation. Physics/Biology/Medicine collaboration</gtr:impact><gtr:outcomeId>546111fad58a36.51369937-1</gtr:outcomeId><gtr:partnerContribution>Access in kind to the protontherapy beamline at the Clatterbridge Cancer Centre</gtr:partnerContribution><gtr:piContribution>We have accessed the protontherapy beamline as part of joint experiments with Dr Andrzej Kacperek.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Mathematics and Physics</gtr:department><gtr:description>EPSRC CDT</gtr:description><gtr:id>84C32494-BAD3-43DA-9D5B-0A5C015899E9</gtr:id><gtr:impact>1 PhD secured for 2013 intake
6 weeks beam time at the GEMINI laser facility at the Central Laser Facility, Didcot (UK)
1 pubblication</gtr:impact><gtr:outcomeId>oPJavHDbmAW-1</gtr:outcomeId><gtr:partnerContribution>Funds and consumables for PhD studentships.
Access to laser driven ion beams

Networking opportunites with the 5 other partners in the CDT</gtr:partnerContribution><gtr:piContribution>Proving radio-biological expertise for laser driven ion beam experiments
Teaching and supervising PhD students</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Prague Protontherapy Centre</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>Collaboration with The Prague Proton Therapy Facility</gtr:description><gtr:id>9624406D-BB77-4408-A93B-C983F45E754B</gtr:id><gtr:impact>Joint poster presented at the US Radiation Research Society Meeting in Las Vegas in September 2014. Physics/Biology/Medicine collaboration</gtr:impact><gtr:outcomeId>54611e2d489333.57877379-1</gtr:outcomeId><gtr:partnerContribution>Access to clinical beamlines at the Prague Protontherapy Centre and Research infrastructure within the University of Dept of Radiation Dosimetry, Nuclear Physics Institute ASCR, as part of a longer term collaboration.</gtr:partnerContribution><gtr:piContribution>Access clincal beams to perform experiments for publication and collaborate with local researchers.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Nuclear Physics</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Laboratori Nazionali del Sud</gtr:department><gtr:description>INFN-LNS Dosimetry</gtr:description><gtr:id>7645FEBF-D94B-420A-A6C2-D0DC8A76353F</gtr:id><gtr:impact>Securing PhD studentship funds from Queen's University Belfast</gtr:impact><gtr:outcomeId>eXBY4cKGjeH-1</gtr:outcomeId><gtr:partnerContribution>Proving MonteCarlo support (Geant4) for PhD student, dosimetric instrumentation/support for exeriments at the INFN-LNS (62 MeV/u proton and carbon ions) Catania Facility</gtr:partnerContribution><gtr:piContribution>Providing radio-biological measurement to validate and support dosimetric measurement
Supervising PhD studentship aimed to model INFN-LNS proton and carbon beam line for radiotherapy and radiobiological applications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Massachusetts General Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Francis H. Burr Proton Therapy Centre</gtr:department><gtr:description>MGH - Held</gtr:description><gtr:id>1CA448B8-B422-4AFA-BCAB-E7D166258484</gtr:id><gtr:impact>1 publication
Access to clinical proton beam facility</gtr:impact><gtr:outcomeId>TtKiPWDz1eS-1</gtr:outcomeId><gtr:partnerContribution>Providing clinical proton beam and dosimetry for radiobiological experiments</gtr:partnerContribution><gtr:piContribution>Collaboration with Drs Harald Paganetti and Dr Kathy Held. Design of radiobiological experiments for passive and scanning proton beam at the MGH</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academy of Sciences of the Czech Republic</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>Nuclear Physics Institute</gtr:department><gtr:description>Collaboration with The Prague Proton Therapy Facility</gtr:description><gtr:id>D9C406F3-575B-490B-94FF-347D1C7CDA2A</gtr:id><gtr:impact>Joint poster presented at the US Radiation Research Society Meeting in Las Vegas in September 2014. Physics/Biology/Medicine collaboration</gtr:impact><gtr:outcomeId>54611e2d489333.57877379-2</gtr:outcomeId><gtr:partnerContribution>Access to clinical beamlines at the Prague Protontherapy Centre and Research infrastructure within the University of Dept of Radiation Dosimetry, Nuclear Physics Institute ASCR, as part of a longer term collaboration.</gtr:partnerContribution><gtr:piContribution>Access clincal beams to perform experiments for publication and collaborate with local researchers.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ENSAR 262010</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>A771DC57-A332-4FB9-B4DA-92F52A35DBFF</gtr:id><gtr:outcomeId>ocBF8fddF7f</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>COST ACTION MP1002</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>244054A6-434E-4C01-B151-C7913CC698A3</gtr:id><gtr:outcomeId>mfifHGy99Kq</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4636962</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Programmatic Funding</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>Ep/K022415/1</gtr:fundingRef><gtr:id>B5C3D0E5-9D01-4210-A8F2-180F1DFA9B10</gtr:id><gtr:outcomeId>56d6a02023b912.23875567</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5934A1F0-AF99-4E24-A5B6-725FBB371110</gtr:id><gtr:title>Biological effectiveness on live cells of laser driven protons at dose rates exceeding 10
 
 Gy/s</gtr:title><gtr:parentPublicationTitle>AIP Advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bf5f29325ae70119a62d9d6bc805467"><gtr:id>0bf5f29325ae70119a62d9d6bc805467</gtr:id><gtr:otherNames>Doria D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>U9RqMuPjxME</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>797EFE94-C9E8-4D04-88FD-19934B0B804C</gtr:id><gtr:title>Relative biological effectiveness (RBE) and out-of-field cell survival responses to passive scattering and pencil beam scanning proton beam deliveries.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e4fd288dfe6d41b1f76a7505b6b73c7"><gtr:id>4e4fd288dfe6d41b1f76a7505b6b73c7</gtr:id><gtr:otherNames>Butterworth KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>pm_13517_27_23022765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16D6866A-C7A6-42F0-814F-48813A3F0825</gtr:id><gtr:title>Investigating the Implications of a Variable RBE on Proton Dose Fractionation Across a Clinical Pencil Beam Scanned Spread-Out Bragg Peak.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6be7b774585511d0aad80d010b76d92"><gtr:id>d6be7b774585511d0aad80d010b76d92</gtr:id><gtr:otherNames>Marshall TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>56d6a1dc1d20f6.92773798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB3D3A2E-1EC3-488A-A7FE-09A0E91499D5</gtr:id><gtr:title>Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: a preclinical assessment.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fadcc6d595f6230d574d361f3950ad85"><gtr:id>fadcc6d595f6230d574d361f3950ad85</gtr:id><gtr:otherNames>Chaudhary P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>5461330602eed8.29452733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D2F1ACC-E703-40B5-91E2-409A2096C83C</gtr:id><gtr:title>Antiproton induced DNA damage: proton like in flight, carbon-ion like near rest.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e270a1165d18c8a3f37597198e671c94"><gtr:id>e270a1165d18c8a3f37597198e671c94</gtr:id><gtr:otherNames>Kavanagh JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_24609_29_23640660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52142C38-2001-4613-B003-8CBF53A2546E</gtr:id><gtr:title>The Radiobiology of Proton Therapy: Challenges and Opportunities Around Relative Biological Effectiveness.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02a692102c18c95a1f2217f9c024bb0c"><gtr:id>02a692102c18c95a1f2217f9c024bb0c</gtr:id><gtr:otherNames>Jones B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa83686292ad6.83140771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>211D7524-00AB-4145-9B8C-D38B9B92AD68</gtr:id><gtr:title>Dose, dose-rate and field size effects on cell survival following exposure to non-uniform radiation fields.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e4fd288dfe6d41b1f76a7505b6b73c7"><gtr:id>4e4fd288dfe6d41b1f76a7505b6b73c7</gtr:id><gtr:otherNames>Butterworth KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>pm_13517_27_22546687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DB66E04-EA14-4429-9262-8F7AFC8553F6</gtr:id><gtr:title>DNA double strand break repair: a radiation perspective.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e270a1165d18c8a3f37597198e671c94"><gtr:id>e270a1165d18c8a3f37597198e671c94</gtr:id><gtr:otherNames>Kavanagh JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>pm_13517_27_23311752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AFFB890-C386-4973-BA80-85A31B11185A</gtr:id><gtr:title>Variations in the Processing of DNA Double-Strand Breaks Along 60-MeV Therapeutic Proton Beams.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fadcc6d595f6230d574d361f3950ad85"><gtr:id>fadcc6d595f6230d574d361f3950ad85</gtr:id><gtr:otherNames>Chaudhary P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>546135ec18b9b9.17929770</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100014</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>